Ken Getz, assistant professor at Tufts Center for the Study of Drug Development (CSDD), reports that oftentimes procedures performed in the last drug development stages are in order to find “supplementary, secondary, tertiary, and exploratory endpoints.” (Carroll) On average, this supplementary data is costing researchers an additional $1.1 million per trial. Moreover, the industry as a whole is impacted by this “extra” research. Eliminating unnecessary data could reduce costs and enhance clinical research performance by making it more timely and accurate. Getz suggests that sponsors should determine in advance exact data and the length of clinical research that is necessary. While additional research can sometimes provide discoveries for the future, it is commonly unnecessary.
To read the full press release, click here.
Need help with protocol design? Contact us at info@pearlirb.com.